Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Hester Biosciences
Join Channel
Consolidated Standalone

Hester Biosciences

₹1758 84.8 | 5.1%

Market Cap ₹1496 Cr.

Stock P/E 79.2

P/B 5.1

Current Price ₹1758

Book Value ₹ 343

Face Value 10

52W High ₹1928.5

Dividend Yield 0.34%

52W Low ₹ 1292.9

Edit Ratio

Hester Biosciences Research see more...

Overview Inc. Year: 1987Industry: Pharmaceuticals & Drugs

Hester Biosciences Ltd manufactures and trades in veterinary vaccines and fitness merchandise in India. It operates through Animal and Poultry healthcare, and Others segments. The corporation offers poultry vaccines for illnesses, along with newcastle disease, infectious bronchitis, infectious bursal sickness, bird pox, egg drop syndrome, reo, marek’s sickness, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, avian encephalomyelitis, and so forth. It also offers vaccines for large animals against Goat Pox, Peste des Petits Ruminants, and Brucellosis diseases, in addition to infections, reproductive problems, theileriosis, and parasitic sicknesses. In addition, the organisation presents feed dietary supplements, such as growth tonic, toxin binder, trace minerals, enzyme training, and bypass fats; disinfectants for farms and equipment; natural and nutrition products; and sanitizers. The corporation additionally exports its products. Hester Biosciences Ltd has a collaboration agreement with Indian Institute of Technology Guwahati to broaden vaccine against COVID-19. The company was founded in 1987 and is located in Ahmedabad, India.

Read More..

Hester Biosciences Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Hester Biosciences Quarterly Results

#(Fig in Cr.) Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 56 56 51 73 75 67 88 70 67 79
Other Income 3 7 3 4 4 3 1 4 1 4
Total Income 58 64 54 78 79 70 89 75 68 83
Total Expenditure 41 46 43 60 56 56 73 57 57 63
Operating Profit 18 18 11 17 23 15 16 18 11 20
Interest 1 2 2 2 4 1 3 8 2 7
Depreciation 5 5 5 5 5 5 5 4 4 4
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 12 11 4 10 14 8 8 5 5 9
Provision for Tax 3 2 2 4 4 3 2 3 2 3
Profit After Tax 8 9 2 6 10 5 5 2 3 6
Adjustments 0 -1 2 1 1 -1 1 2 1 -1
Profit After Adjustments 8 8 4 7 11 5 6 4 4 5
Adjusted Earnings Per Share 10 9.1 4.7 8.2 13.1 5.3 6.9 4.8 4.7 5.8

Hester Biosciences Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 65 69 90 101 123 136 178 183 214 235 266 304
Other Income 0 1 0 1 0 3 7 6 5 14 15 10
Total Income 65 70 90 102 124 138 185 190 219 249 281 315
Total Expenditure 43 45 65 67 82 89 110 128 146 175 216 250
Operating Profit 22 25 26 34 41 50 75 62 73 74 66 65
Interest 3 6 5 4 3 4 7 7 7 4 9 20
Depreciation 4 5 6 6 7 10 12 13 13 17 21 17
Exceptional Income / Expenses 0 0 3 0 0 0 0 0 -3 0 0 0
Profit Before Tax 14 13 18 25 31 36 57 41 50 54 40 27
Provision for Tax 5 4 5 6 8 13 16 10 15 14 12 10
Profit After Tax 9 9 13 19 23 23 41 31 35 39 28 16
Adjustments 0 0 0 0 1 3 1 -2 -0 -0 -1 3
Profit After Adjustments 9 9 14 19 24 26 42 29 34 39 27 19
Adjusted Earnings Per Share 10.9 11.1 16 22.6 27.7 30.1 48.9 34.3 40.5 46.2 31.3 22.2

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 13% 13% 14% 15%
Operating Profit CAGR -11% 2% 6% 12%
PAT CAGR -28% -3% 4% 12%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -2% -7% 2% 34%
ROE Average 10% 14% 17% 17%
ROCE Average 10% 14% 17% 18%

Hester Biosciences Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 67 75 85 102 122 141 177 201 228 260 280
Minority's Interest 1 1 3 5 5 4 4 5 8 7 9
Borrowings 14 16 32 33 45 37 58 76 83 165 185
Other Non-Current Liabilities 3 5 6 8 4 8 11 20 31 33 48
Total Current Liabilities 39 45 35 38 38 55 49 83 61 97 149
Total Liabilities 124 142 160 186 213 244 299 387 411 562 670
Fixed Assets 38 54 60 65 103 110 145 143 133 237 259
Other Non-Current Assets 36 31 41 47 30 35 13 85 117 130 183
Total Current Assets 50 57 60 74 80 98 142 159 162 195 228
Total Assets 124 142 160 186 213 244 299 387 411 562 670

Hester Biosciences Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 3 2 1 6 5 11 12 41 24 21 25
Cash Flow from Operating Activities 12 9 20 19 35 38 47 37 58 9 24
Cash Flow from Investing Activities -23 -15 -21 -13 -30 -26 -22 -74 -38 -117 -77
Cash Flow from Financing Activities 10 7 7 -7 2 -11 3 19 -18 112 42
Net Cash Inflow / Outflow -1 2 5 -1 6 1 28 -19 1 4 -12
Closing Cash & Cash Equivalent 2 4 6 5 11 12 41 24 21 25 13

Hester Biosciences Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 10.88 11.11 15.98 22.57 27.68 30.12 48.86 34.29 40.47 46.22 31.3
CEPS(Rs) 15.87 17.14 22.23 29.31 35.02 38.47 61.65 51.81 56.44 65.9 57.28
DPS(Rs) 2 2 3.1 4.1 5.3 10 11 6.6 10 10 8
Book NAV/Share(Rs) 79.11 88.18 99.83 119.56 143.35 165.32 208.61 236.36 268.38 305.61 328.82
Core EBITDA Margin(%) 32.88 34.61 27.28 32.42 32.71 34.65 38.21 30.23 31.97 25.32 18.81
EBIT Margin(%) 26.54 28.07 24.63 27.7 27.46 29.44 35.66 26.57 26.41 24.3 18.46
Pre Tax Margin(%) 21.64 18.92 19.72 24.08 24.67 26.48 31.93 22.55 23.33 22.58 14.98
PAT Margin (%) 13.62 12.97 14.5 18.62 18.17 16.91 22.85 16.92 16.16 16.67 10.46
Cash Profit Margin (%) 20.27 20.64 20.49 24.21 23.75 23.99 29.45 24.05 22.36 23.67 18.18
ROA(%) 8.28 6.89 8.84 11.08 11.43 10.1 14.97 9.04 8.7 8.11 4.55
ROE(%) 14.28 12.88 16.73 20.56 20.38 17.57 25.59 16.38 16.16 16.17 10.39
ROCE(%) 20.1 17.78 17.26 18.98 19.75 20.2 26.64 16.53 17.33 14.12 9.6
Receivable days 80.59 75.19 62.94 77.96 76.8 78.7 66.77 90.92 91.49 80.5 91.87
Inventory Days 160.79 172.29 127.96 111.14 97.55 97.89 92.8 114.27 107.25 106 109.08
Payable days 115.6 163.83 67.54 96.74 85.39 120.32 106.73 187.68 174.82 129.73 113.04
PER(x) 11.39 7.99 29.29 22.13 27.57 53.25 31.62 26.98 47.36 58.75 48.58
Price/Book(x) 1.57 1.01 4.69 4.18 5.32 9.7 7.41 3.91 7.14 8.88 4.62
Dividend Yield(%) 1.61 2.25 0.66 0.82 0.69 0.62 0.71 0.71 0.52 0.37 0.53
EV/Net Sales(x) 2.08 1.72 4.96 4.74 5.72 10.44 7.66 4.82 8 10.67 5.81
EV/Core EBITDA(x) 6.12 4.71 17.5 13.96 16.99 28.5 18.12 14.31 23.37 34.01 23.52
Net Sales Growth(%) 34.89 6.06 30.4 12.06 22.02 10.42 30.99 2.92 16.95 9.65 13.23
EBIT Growth(%) 20 12.21 14.61 25.53 20.7 16.63 58.1 -23.3 16.45 1.51 -14.06
PAT Growth(%) 21.15 1.05 46.01 43.35 18.8 1.23 76.41 -23.82 11.92 13.79 -29
EPS Growth(%) 21.7 2.1 43.82 41.19 22.66 8.81 62.24 -29.83 18.03 14.2 -32.28
Debt/Equity(x) 0.48 0.64 0.65 0.58 0.54 0.49 0.51 0.6 0.46 0.86 0.96
Current Ratio(x) 1.28 1.26 1.71 1.94 2.1 1.8 2.91 1.91 2.63 2.01 1.53
Quick Ratio(x) 0.48 0.47 0.88 1.06 1.22 1.07 1.87 1.14 1.62 1.23 0.96
Interest Cover(x) 5.41 3.07 5.02 7.67 9.84 9.95 9.57 6.61 8.59 14.16 5.31
Total Debt/Mcap(x) 0.31 0.64 0.14 0.14 0.1 0.05 0.07 0.15 0.06 0.1 0.21

Hester Biosciences Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 53.73 53.73 53.73 53.73 53.73 53.73 53.73 53.73 53.73 53.73
FII 0.8 0.92 0.72 0 0.45 0.45 0.45 0.42 0.43 0.43
DII 0.02 0.04 0.03 0.65 0.03 0 0 0 0 0
Public 45.45 45.31 45.51 45.61 45.78 45.82 45.82 45.85 45.84 45.84
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 129.73 to 113.04days.

Cons

  • Company has a low return on equity of 14% over the last 3 years.
  • Stock is trading at 5.1 times its book value.
  • The company has delivered a poor profit growth of 4% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Hester Biosciences News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!